Lupin to sell generic HIV drug

Lupin Ltd announced that it has received a tentative approval from the US Food and Drug Administration (FDA) to market a generic version of the Prezista tablets, which are used for the treatment of HIV-1 infections. The generic version of the Janssen Products’ Prezista is the AB-rated generic equivalent of the original drug, the company said. Prezista tablets have annual sales of $12 billion in the US, Lupin added. Lupin would market the tablets in strengths of 75 mg, 150 mg, 300 mg, 400 mg, 600 mg and 800 mg.